Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors

Author(s): Wei-Hua Shao, Lei-Yun Wang, Ji-Ye Yin*

Journal Name: Current Pharmacogenomics and Personalized Medicine
Formerly Current Pharmacogenomics

Volume 16 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.

Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 12 November, 2018
Page: [108 - 117]
Pages: 10
DOI: 10.2174/1875692116666180821152601

Article Metrics

PDF: 41